INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

INO-3107 shows promise in reducing surgeries for RRP patients

PLYMOUTH MEETING, Pa. - INOVIO (NASDAQ: INO), a biotechnology company with a market capitalization of approximately $69 ...
Hosted on MSN

INOVIO Announces Promising Immunology Data for INO-3107 in RRP Treatment

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled encouraging new immunology data for its lead product candidate, INO-3107, which is designed to treat recurrent respiratory papillomatosis (RRP) ...
Yahoo Finance

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients ...